AXIM - VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024 | Benzinga
Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM's Diagnostic Research Programs in Dry Eye Disease and Parkinson's
SAN DIEGO, CA, March 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –AXIM Biotechnologies, Inc. (OTCQB:AXIM) ("AXIM Biotech," "AXIM" or "the Company"), an international healthcare diagnostic solutions development company, today released a fireside chat interview conducted with its CEO John Huemoeller II and Tony Noto at the 2024 Benzinga Virtual Healthcare Summit. During the presentation, Mr. Huemoeller shares insights into the Company's work with its two FDA-cleared ophthalmological diagnostic assays currently being marketed to clinicians throughout the country as well as research being conducted in its Parkinson's diagnostic program.
The presentation can be viewed here: https://aximbiotech.com/presentations/
"We're in the diagnostic solutions segment using teardrops and have mastered a couple of tests already, Lactoferrin which is for dry eye disease, and IgE which is for allergies," said John Huemoeller II, CEO of AXIM Biotechnologies during the presentation. "So if you go into your eye doctor and you have red, scratchy, itchy eyes, [the question becomes] ‘do you ...